Abstract

Targeted drug delivery represents a groundbreaking approach in the field of precision medicine, offering significant advancements in cancer treatment. This method focuses on delivering therapeutic agents directly to cancer cells while minimizing exposure to healthy tissues, thereby reducing side effects and enhancing therapeutic efficacy. Recent innovations in nanotechnology, bioengineering, and molecular targeting have enabled the development of highly specific delivery systems, such as liposomes, nanoparticles, and antibody-drug conjugates. These technologies facilitate the controlled release of drugs at the tumor site, improving drug stability and bioavailability. This review explores the latest advancements in targeted drug delivery systems, their mechanisms, and their impact on the personalized treatment of various cancers. Emphasis is placed on the potential of these technologies to overcome the challenges of drug resistance and tumor heterogeneity, offering new hope for more effective and individualized cancer therapies